MHRA Updates Clinical Investigation Guidance : What Manufacturers Need to Know

The MHRA’s “Clinical investigations for medical devices” guidance acts as the official framework for when and how medical device manufacturers must notify and obtain approval for clinical investigations in the UK (Great Britain and Northern Ireland). Given evolving regulatory landscapes including post‑Brexit UK regulations (UK Medical Devices Regulations 2002 (UK MDR 2002)) and continued alignment with EU rules for Northern Ireland the update clarifies key definitions and submission pathways. For manufacturers worldwide (including those outside the UK) planning clinical investigations in the UK or with UK market ambitions aligning with this updated guidance is critical to avoid compliance issues, delays, or invalid applications.

WHAT CHANGED IN CLINICAL INVESTIGATION GUIDANCE NOVEMBER 2025

Updated Flow Chart & Accompanying Guidance for Great Britain studies

As of 24 November 2025, MHRA published a revised flow‑chart and supporting guidance aimed at helping sponsors/manufacturers decide whether their intended study qualifies as a “clinical investigation” requiring formal notification.

The updated guidance gives clearer criteria and examples improving predictability and reducing ambiguity.

Clarification on When Notification Is Not Required

Under the updated guidance, certain categories of studies do not require notification e.g., bench testing, retrospective data reviews, certain usability-only studies, or post‑market follow-up (PMCF) studies for devices already UKCA/CE marked and used strictly within their intended purpose.

This helps manufacturers and sponsors avoid unnecessary regulatory overhead for lower-risk or non-interventional studies.

Differentiation Between Great Britain and Northern Ireland Regulatory Paths

The guidance reiterates that clinical investigations in Great Britain follow UK MDR 2002. In contrast, studies in Northern Ireland remain subject to the EU regulations (EU Medical Device Regulation 2017/745 (EU MDR)) due to the Northern Ireland Protocol.

For multi‑site studies spanning GB and NI, submission must respect the applicable regulation depending on the sites involved.

Reinforced Submission & Application Requirements, Validation Process, and Timelines

The updated guidance underscores the requirement to notify MHRA at least 60 days prior to initiating a clinical investigation in GB for devices not already UKCA/CE marked for their intended use.

Applications must be submitted via the official portal (IRAS), and must include comprehensive documentation: device description, clinical investigation plan/protocol, risk analysis, investigator/site info, ethics approvals (where relevant), and other technical/clinical data.

Once submitted and validated, MHRA confirms within 5 working days and formally begins the 60‑day review period. During this period, safety, performance, and design of the proposed investigation are evaluated.

Non-substantial amendments (administrative) and substantial amendments (protocol change, device change, new site, etc.) are defined; all require appropriate submissions before implementation.

Special provisions also exist for early termination, temporary halt of studies, along with reporting obligations (e.g., serious adverse events, deviation reporting, final reports).

NEW INCENTIVE: PILOT FEE WAIVER PROGRAMME FOR MICRO & SMALL ENTERPRISES (JAN TO MAR 2026)

A major new feature introduced in this update is a pilot scheme by MHRA offering fee waivers for clinical investigation applications from eligible micro or small UK enterprises.

Pilot Window & Scope

Start Date: 4 January 2026
End Date: 31 March 2026 (or earlier, if waiver quota is exhausted)
Eligible Device Classes: Class I, IIa, or IIb medical devices

Eligibility Criteria — “Innovative Device” Concept

To qualify, devices must meet all three of these criteria:

Be new or a novel modification of existing technologies.
Address a clinical need for which there is no existing approved solution in the UK.
Have the potential for scalability benefits should extend to patients, care providers, or the healthcare system at large.

Application Requirements for Waiver

To request the waiver, applicants must:

Have been granted SME status by MHRA before application.
Submit a valid clinical investigation notification between 4 Jan and 31 Mar 2026.
Included in the cover letter: MHRA SME approval letter, explicit waiver request, and a justification describing how the device meets the innovation criteria.

If the waiver is not granted( e.g., quota exceeded or criteria not met standard fees apply )

This pilot represents a strategic opportunity for small UK‑based manufacturers to reduce financial barriers, encouraging early‑stage innovations and accelerating device development.

IMPLICATIONS & CONSIDERATIONS FOR MANUFACTURERS

Given the updates, manufacturers (or sponsors) planning clinical investigations in the UK should take note of the following:

Use the latest flow chart & guidance (Nov 2025 version) to assess whether your study requires formal notification — outdated or pre‑update assessments may lead to non‑compliance.
For already CE/UKCA‑marked devices used within intended purpose: many post‑market follow-up or usability‑only studies may avoid notification — reducing regulatory burden.
If planning cross‑UK studies (GB + Northern Ireland), be aware of dual regulatory frameworks (UK MDR for GB, EU MDR for NI) — plan submissions accordingly (single or dual application depending on scope).
Leverage the pilot fee waiver if you are a small UK-based enterprise with an innovative device — families of early-stage device makers should consider timing submissions to fall within the Jan–Mar 2026 window.
Ensure robust documentation: clinical investigation plans, risk analyses, safety monitoring procedures, statistical plans, investigator/site data, ethics approvals (as applicable). Missing or weak documentation can delay validation or lead to refusal.
Plan for post‑approval obligations: SAE reporting, amendments, final reports, study deviations — these remain mandatory.

WHAT THIS MEANS FOR GLOBAL MANUFACTURERS & SPONSORS (INCLUDING NON‑UK)

Even for manufacturers or sponsors outside the UK for example, companies based in India, EU, or other regions these updates are relevant if you intend to conduct clinical investigations in the UK (Great Britain or Northern Ireland) or aim for UK market entry under UKCA/CE UKNI regime.

You must assess whether your planned study qualifies under the updated flow chart.
Consider partnering with UK-based entities (e.g., distributors, CROs, or UK Responsible Persons) if needed.
For small/innovative devices, aligning with the waiver pilot might provide cost advantage though note that SME status and UK‑based entity requirements apply.

Given that you work in medical‑device regulatory consulting and help manufacturers internationally (EU, USA, India, China), this update is significant. It’s a chance to advise clients looking to expand to the UK about a more streamlined, and in some cases less costly, pathway especially for innovative, small‑company devices.

RECOMMENDED ACTION PLAN FOR MANUFACTURERS / CONSULTANTS

SI.NO	Step	Action / Checkpoint
1	Gap analysis	Review your device portfolio and proposed studies against the updated flow chart to confirm whether notification is required.
2	Documentation readiness	Ensure you have up-to-date device technical documentation, clinical investigation plan / protocol, risk analysis, investigator/site details, consent forms (if relevant), etc.
3	For small/innovative devices	If eligible, apply for MHRA SME status now, so you can benefit from the 2026 waiver pilot. Include waiver request and justification in application cover letter.
4	Submission timing	For waiver‑eligible submissions, target the window 4 Jan – 31 Mar 2026. For other submissions, ensure a minimum 60‑day lead time before intended study start.
5	Regulatory strategy for multi‑region studies	If study sites span Great Britain and Northern Ireland, plan regulatory routes carefully possibly aligning with both UK MDR and EU MDR requirements.
6	Post‑submission compliance	Prepare for follow‑up obligations (SAE reporting, amendments, final reports) as per updated MHRA requirements.

IN SUMMARY

The November 2025 update by MHRA represents more than just subtle tweaks: it offers clearer decision‑making tools, refined definitions, and a strategic opportunity for small, innovative companies through the fee‑waiver pilot. For regulatory consultants and device manufacturers, this signals a shift toward more transparent, accessible, and innovative‑friendly clinical investigation processes in the UK. Proper alignment with these updates in planning, documentation, and timing can reduce regulatory friction, save costs, and accelerate market entry.